Compare Agilent Technologies Inc (A) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Macy's Inc — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Macy's Inc trades at $22.66 (market cap $6.08B). The key difference: Agilent Technologies Inc is far larger — about 6.1× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| A | M | |
|---|---|---|
Market Cap | $37.04B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $25.96 |
52-Week Low | $110.24 | $11.90 |
Enterprise Value | $38.59B | $9.90B |
Dividend Yield | 0.78% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Macy's (M) trades at $23.13, down 0.52% on the day, with technical indicators showing a bullish trend supported by moving averages. The stock shows attractive valuation metrics with a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. The company's 'Bold New Chapter' strategy is gaining traction with improved comparable sales and digital growth, supported by Berkshire Hathaway's new 3.04 million-share position disclosed in Q1 2026.
Macy's presents a compelling value opportunity with strong institutional interest and operational improvements, though investors face risks from retail sector headwinds and margin pressure. The consensus price target of $23.80 suggests modest upside potential, while execution on turnaround initiatives remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
